News >

FDA Approval Sought for Liso-Cel in Large B-Cell Lymphoma

OncLive Staff
Published: Wednesday, Dec 18, 2019

Jeremy Abramson, MD, associate professor of medicine, Harvard Medical School, Boston, and director of the Jon and JoAnn Hagler Center for Lymphoma at Massachusetts General Hospital Cancer Center

Jeremy Abramson, MD

Bristol-Myers Squibb has submitted a biologics license application (BLA) to the FDA seeking approval of the anti-CD19 CAR T-cell therapy lisocabtagene maraleucel (liso-cel) for the treatment of adult patients with relapsed/refractory large B-cell lymphoma (LBCL) after at least 2 prior therapies.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication